| |DECEMBER 20238Lupin Limited has announced that the United States Food and Drug Administration (US FDA) has approved its Abbreviated New Drug Application for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg, to market a generic equivalent of Kowa Company Limited's Livalo Tablets, 1 mg, 2 mg, and 4 mg.Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in Adults with primary hyperlipidemia, Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH), as per medicaldialogues. Lupin's Pithampur factory in India will manufacture the product. Pitavastatin Tablets (RLD Livalo) has expected annual sales in the United States of $298 million (IQVIA MAT September 2023).Lupin is a worldwide pharmaceutical firm based in Mumbai, India that focuses on innovation. The Company develops and commercializes a diverse variety of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, South Africa, and Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East. The company focuses in the cardiovascular, anti-diabetic, and respiratory sectors, and it also has a strong presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health segments.Lupin is the third-largest pharmaceutical firm in the United States in terms of prescriptions. In FY23, the firm spent 7.9 percent of its revenue on research & development. Lupin has 15 production facilities, 7 research centers, and over 20,000 employees worldwide, and has been honored as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals industry on several occasions. POMerck, known as MSD outside the United States and Canada, and Caraway Therapeutics, Inc. announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment and contingent milestone payments. Merck will incur the upfront payment in the fourth quarter of 2023 and reflect it in non-GAAP earnings."Caraway's multidisciplinary approach has yielded important progress in evaluating novel mechanisms of modulation of lysosomal function with potential for the treatment of progressive neurodegenerative diseases," said George Addona, senior vice president, discovery, preclinical development and translational medicine, Merck Research Laboratories. "We look forward to applying our expertise to build upon this work with the goal of developing much needed disease-modifying therapies for these conditions."Caraway is a preclinical biopharmaceutical company pursuing innovative approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company has built a pipeline of novel, small-molecule therapeutics for the treatment of genetically defined neurodegenerative and rare diseases, as per pharmabiz."This important milestone is a testament to the hard work and dedication of the Caraway team and our mission to develop therapeutics with the potential to alter the progression of devasting neurodegenerative diseases and help patients," said Martin D. Williams, chief executive officer, Caraway Therapeutics. "This acquisition leverages Merck's industry-leading research and development capabilities to help further advance our discovery and preclinical programs. We thank and appreciate our investors, including SV Health Investors and its Dementia Discovery Fund, AbbVie Ventures, Amgen Ventures, Eisai Innovation and MRL Ventures Fund for their support." POLUPIN BAGS USFDA NOD FOR CHOLESTEROL LOWERING DRUG PITAVASTATINMERCK TO ACQUIRE CARAWAY THERAPEUTICS FOR $610 MILLIONTOP STORIES
< Page 7 | Page 9 >